The Experts below are selected from a list of 207249 Experts worldwide ranked by ideXlab platform
Lihsueh C Lee - One of the best experts on this subject based on the ideXlab platform.
-
Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. Annals of neurology 44
1998Co-Authors: Sid Gilman, Larry Junck, Kirk A Frey, Mary Lohman, Susan Martorello, Lihsueh C Lee, Roderick Little, Thierry M., Er Borght, Douglas T M. JewettAbstract:We used [“Cldihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (vMAT2), with posi-tron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61 % in the caudate nucleus (p = 0.002) and 58 % in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26 % in the caudate nucleus (p = 0.05) and 24 % in the putamen (p = 0.1 1). Mean blood-to-brain [“Cldihydrotetrabenazine transport (K,) was significantly differ-ent between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K, was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal W T 2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease
-
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography
Annals of Neurology, 1996Co-Authors: Sid Gilman, Larry Junck, Robert A Koeppe, Kirk A Frey, Roderick J A Little, Thierry Vander Borght, Mary Lohman, Susan Martorello, Lihsueh C LeeAbstract:We used [11C]dihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (VMAT2), with positron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61% in the caudate nucleus (p = 0.002) and 58% in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26% in the caudate nucleus (p = 0.05) and 24% in the putamen (p = 0.11). Mean blood-to-brain [11C]dihydrotetrabenazine transport (K1) was significantly different between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K1 was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal VMAT2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease.
Kirk A Frey - One of the best experts on this subject based on the ideXlab platform.
-
Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. Annals of neurology 44
1998Co-Authors: Sid Gilman, Larry Junck, Kirk A Frey, Mary Lohman, Susan Martorello, Lihsueh C Lee, Roderick Little, Thierry M., Er Borght, Douglas T M. JewettAbstract:We used [“Cldihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (vMAT2), with posi-tron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61 % in the caudate nucleus (p = 0.002) and 58 % in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26 % in the caudate nucleus (p = 0.05) and 24 % in the putamen (p = 0.1 1). Mean blood-to-brain [“Cldihydrotetrabenazine transport (K,) was significantly differ-ent between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K, was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal W T 2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease
-
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography
Annals of Neurology, 1996Co-Authors: Sid Gilman, Larry Junck, Robert A Koeppe, Kirk A Frey, Roderick J A Little, Thierry Vander Borght, Mary Lohman, Susan Martorello, Lihsueh C LeeAbstract:We used [11C]dihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (VMAT2), with positron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61% in the caudate nucleus (p = 0.002) and 58% in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26% in the caudate nucleus (p = 0.05) and 24% in the putamen (p = 0.11). Mean blood-to-brain [11C]dihydrotetrabenazine transport (K1) was significantly different between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K1 was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal VMAT2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease.
Sid Gilman - One of the best experts on this subject based on the ideXlab platform.
-
Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. Annals of neurology 44
1998Co-Authors: Sid Gilman, Larry Junck, Kirk A Frey, Mary Lohman, Susan Martorello, Lihsueh C Lee, Roderick Little, Thierry M., Er Borght, Douglas T M. JewettAbstract:We used [“Cldihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (vMAT2), with posi-tron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61 % in the caudate nucleus (p = 0.002) and 58 % in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26 % in the caudate nucleus (p = 0.05) and 24 % in the putamen (p = 0.1 1). Mean blood-to-brain [“Cldihydrotetrabenazine transport (K,) was significantly differ-ent between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K, was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal W T 2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease
-
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography
Annals of Neurology, 1996Co-Authors: Sid Gilman, Larry Junck, Robert A Koeppe, Kirk A Frey, Roderick J A Little, Thierry Vander Borght, Mary Lohman, Susan Martorello, Lihsueh C LeeAbstract:We used [11C]dihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (VMAT2), with positron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61% in the caudate nucleus (p = 0.002) and 58% in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26% in the caudate nucleus (p = 0.05) and 24% in the putamen (p = 0.11). Mean blood-to-brain [11C]dihydrotetrabenazine transport (K1) was significantly different between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K1 was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal VMAT2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease.
Susan Martorello - One of the best experts on this subject based on the ideXlab platform.
-
Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. Annals of neurology 44
1998Co-Authors: Sid Gilman, Larry Junck, Kirk A Frey, Mary Lohman, Susan Martorello, Lihsueh C Lee, Roderick Little, Thierry M., Er Borght, Douglas T M. JewettAbstract:We used [“Cldihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (vMAT2), with posi-tron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61 % in the caudate nucleus (p = 0.002) and 58 % in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26 % in the caudate nucleus (p = 0.05) and 24 % in the putamen (p = 0.1 1). Mean blood-to-brain [“Cldihydrotetrabenazine transport (K,) was significantly differ-ent between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K, was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal W T 2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease
-
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography
Annals of Neurology, 1996Co-Authors: Sid Gilman, Larry Junck, Robert A Koeppe, Kirk A Frey, Roderick J A Little, Thierry Vander Borght, Mary Lohman, Susan Martorello, Lihsueh C LeeAbstract:We used [11C]dihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (VMAT2), with positron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61% in the caudate nucleus (p = 0.002) and 58% in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26% in the caudate nucleus (p = 0.05) and 24% in the putamen (p = 0.11). Mean blood-to-brain [11C]dihydrotetrabenazine transport (K1) was significantly different between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K1 was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal VMAT2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease.
Mary Lohman - One of the best experts on this subject based on the ideXlab platform.
-
Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. Annals of neurology 44
1998Co-Authors: Sid Gilman, Larry Junck, Kirk A Frey, Mary Lohman, Susan Martorello, Lihsueh C Lee, Roderick Little, Thierry M., Er Borght, Douglas T M. JewettAbstract:We used [“Cldihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (vMAT2), with posi-tron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61 % in the caudate nucleus (p = 0.002) and 58 % in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26 % in the caudate nucleus (p = 0.05) and 24 % in the putamen (p = 0.1 1). Mean blood-to-brain [“Cldihydrotetrabenazine transport (K,) was significantly differ-ent between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K, was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal W T 2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease
-
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography
Annals of Neurology, 1996Co-Authors: Sid Gilman, Larry Junck, Robert A Koeppe, Kirk A Frey, Roderick J A Little, Thierry Vander Borght, Mary Lohman, Susan Martorello, Lihsueh C LeeAbstract:We used [11C]dihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (VMAT2), with positron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 Normal Control subjects. Specific binding in the striatum was significantly reduced in the multiple system atrophy patients as compared with the Normal Control Group, with average reductions of 61% in the caudate nucleus (p = 0.002) and 58% in the putamen (p = 0.009). Smaller reductions were found in the sporadic olivopontocerebellar atrophy Group, averaging 26% in the caudate nucleus (p = 0.05) and 24% in the putamen (p = 0.11). Mean blood-to-brain [11C]dihydrotetrabenazine transport (K1) was significantly different between Groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy Group diminished compared with the Normal Control Group. Cerebellar K1 was not significantly decreased in the multiple system atrophy Group. The finding of reduced striatal VMAT2 in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal pathology, indicating that some may later develop symptomatic extrapyramidal disease.
